Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie

Sign up for our daily newsletter

Gilead to buy YM BioSciences for about $465 million

11:06 am by | 0 Comments

(Reuters) - Gilead Sciences Inc will buy Canada's YM BioSciences Inc for about $465 million to gain access to its blood and immune cell disorder drugs.

Gilead said it will pay $2.95 per YM share.

YM shares closed at C$1.66 on Tuesday on the Toronto Stock Exchange.

(Reporting by Adithya Venkatesan and Shounak Dasgupta in Bangalore; Editing by Roshni Menon)


Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Hear the latest news first

Get our daily newsletter or follow us.